Stem Cells and Regenerative Therapy
Stem Cells and Regenerative Medicine hold the promise of repairing damaged or injured tissues and stimulating the bodys own healing mechanism. This is accomplished using the latest technologies to help the body heal. Stem cells and Regenerative Medicine provide effective solutions that heal the body from within. Midwest Integrated Medical Center in Hudson, Wisconsin is proud to be a leader in helping patients repair by unlocking the regenerative healing power of the human body!
Sometimes surgery isnt an option for pain relief, or perhaps, previous treatments havent worked. In such instances, stem cell and regenerative medicine techniques may be a solution. Pain-relief experts at Midwest Integrated Medical Center can evaluate whether youre a candidate for regenerative medicine. This comprehensive alternative treatment is beneficial for chronic pain sufferers of knee pain, shoulder pain, hip pain, wrist pain, elbow pain, arthritis, and so much more. Book your stem cells and regenerative medicine consultation appointment today, either online or over the phone.
Stem Cells and Regenerative medicine involves using your body to heal itself, using naturally occurring cells and specialized fluids. Midwest Integrated Medical Center provides patients with amniotic allograft treatments for regenerating healing purposes. These treatments are made up of hyaluronic acid, regenerative cells, and cytokines, which are all powerful growth factors that help regenerate your bodys tissues.
Once youre injected with the amniotic allograft serum, the growth factors start to work, triggering cell growth in the area injected. Over the following few weeks, cells grow and divide, forming new tissues. This helps heal damaged or injured areas you have, without going through a surgical procedure.
Stem Cells and Regenerative medicine with amniotic allograft treatments is beneficial for healing many types of bone and soft tissue problems, including arthritis. The injections may help heal your:
Stem Cells are primitivecells that can develop into any other type of cell in your body. Since they can become any type of cell including muscle, bone or ligament cells, they beginhealing those injured tissues. Your body is continuously rebuilding, and Amniotic Allograft Therapy delivers a high concentration of growth factors into the injured or weaken area which will promote natural healing.
While there have been controversies surrounding the source of stem cells for healing purposes, Midwest Integrated Medical Center is committed to preservingthe value anddignity of human life. We are proud of our partnership with a biologics provider which obtains placental and amniotic stem cells with parental consent from live human births. At the time of Cesarean delivery (also known as C-section), the baby is delivered and the placenta and fluid, which are typically discarded, are saved. All tissues are then tested to ensure viability and safety. Tissues are processed to the highest standards in a state-of-the-art American Association of Tissue Banks (AATB) accredited facility and are subjected to stringent testing prior to release.
Amniotic Allografts are prepared and injected into the damaged or weakened area where they allow the body to heal at an accelerated rate. These growth factors pinpoint the degenerated tissue and heal them by regenerating new cells and tissue. According to Midwest Integrated Medical Providers, patients can experience a remarkable decrease in pain and significant improvement in their range of motion within only a few weeks of one treatment.
Amniotic Allograft Therapy offers hope and healing! Get YOUR life back without painful surgery and costly drugs!
***Because we cannot test the amniotic tissues for stem cells without killing the stem cells in the process we cannot claim there are live stem cells in the Amniotic Allograft. The FDA has deemed this a rule. The company we work with tests four random samples from every placenta they collect. After the Amniotic Allograft has been processed they are cryofrozen to -80 C. When the Amniotic Allograft are then warmed they find 95% of the stem cells are viable, alive and can then go to work. However, because the sample that goes in the patients cannot be tested without killing the stem cells we cannot claim a 95% viability rate. All we can do is show you what happens with patients after being injected with Amniotic Allograft. The theory is that these tissues (cartilage, ligament, tendon, muscles, bone, discs, and nerves) begin to repair themselves.
Our In-Office Procedure
Because you are kickstarting your body into making new tissues, it does take some time for your regenerative medicine treatment to start working. Some patients report a dramatic reduction in their pain levels in as little as two weeks, while others experience improvement within a few months. It just depends on how quickly your body responds to the treatment.
Possibly, depending on how quickly you heal and the severity of your injury. If you see improvement but you dont notice significant improvement, your doctor might suggest repeating the treatment, just to further boost healthy tissue growth. They can let you know what to expect during your consultation and assessment appointment.
They are injections after all, so you may feel a bit of stinging, but only for a few seconds. Most patients describe a temporary burning sensation, although it doesnt last long. If youre sensitive to pain or are getting the injections in a sensitive area, your practitioner can apply a topical numbing product. This product decreases some of the stinging sensation from the injection and minimizes your discomfort.
The use of cellular therapy is a modern new approach, which can address both the inflammation and degeneration in hopes of providing a non-surgical repair for the patient. Live cell allogenic amniotic fluid is a rich source of epithelial progenitor cells and mesenchymal cells and carries an intrinsic antibacterial component. The factors contained in this medium will provides a matrix which solves both the acute inflammation issue as well as the long-term degeneration issue, which will ultimately lead to fewer cases that go on to surgery and more cases that will return to full function and normal activities of daily living. This is an active and growing field of medicine that does have a lack of understanding by many of the insurance carriers, adjusters, and other medical professionals, but when this therapy is applied judiciously to the proper candidates has profound positive results.
The use of biologic tissue transplants offers an improved quality of life for many surgical patients. As advances in the procurement and processing of biologics continue to evolve, and the numbers and types of biologic tissue forms continue to expand, so do the challenges related to tissue management and compliance with all applicable regulations and guidelines.
PalinGen products follow all appropriate guidelines, in testing as well as processing and ultimately delivery of a healthy viable allograft to the patient to amplify tissue regeneration.
The risks of using PalinGen products is exceptionally small, but a very small risk of disease transmission cannot be 100% ruled out, none has ever been reported, no adverse side effects has ever been reported. But within every product, there is some risk, and you are being informed today of all the precautions we take in bringing the product to you, and that a potential risk does exist no matter how small, when this product is used on you or in you.
Call us today 715-808-0716 or to schedule a private consultation with our staff.
You may also book your consultation by clicking below.
See the original post:
Stem Cell Therapy And Regenerative Medicine : Midwest ...
- In situ repair abilities of human umbilical cordderived mesenchymal stem cells and autocrosslinked hyaluronic acid gel complex in rhesus monkeys with... - May 23rd, 2020
- UH studying use of convalescent plasma to improve health of COVID-19 patients - Crain's Cleveland Business - May 23rd, 2020
- COVID-19: Recommendations for Treating MS and Related... : Neurology Today - LWW Journals - May 21st, 2020
- New hybrid embryos are the most thorough mixing of humans and mice yet - Science News - May 20th, 2020
- Hotel in Spain requires two negative Covid-19 tests to check in with a free antibody test during your stay - CNBC - May 20th, 2020
- 'Outpatient Is Still Chaos': What We Heard This Week - MedPage Today - May 20th, 2020
- Sumit Dewanjee, MD, is being recognized by Continental Who's Who - PRNewswire - May 7th, 2020
- Results From Pivotal Phase 2/3 Study of Emapalumab in Patients With Primary HLH Published in New England Journal of Medicine - BioSpace - May 7th, 2020
- COVID-19 Impact and Recovery Analysis | Global Cell Isolation Market 2020-2024 | Evolving Opportunities with Agilent Technologies Inc. and Becton,... - May 7th, 2020
- Stem Cell Alopecia Treatment Market Detailed Analysis of Current Industry Figures With Forecasts Growth by 2026 - 3rd Watch News - May 7th, 2020
- AMC to use stem cell therapy in treating graft-versus-host disease - Korea Biomedical Review - May 7th, 2020
- Drumming class finds a new rhythm with creative connections - Yes! Weekly - May 7th, 2020
- Drumming class finds a new rhythm with creative connections - Wake Forest University News Center - May 5th, 2020
- Insights on the Worldwide Cell Expansion Industry to 2027 - Analysis and Forecasts - Yahoo Finance UK - May 5th, 2020
- These 5 Houston-area research institutions have bright minds at work to battle COVID-19 - InnovationMap - May 5th, 2020
- GCC Condemns Israeli Plans to Annex Parts of the West Bank - Asharq Al-awsat English - May 2nd, 2020
- Jerusalem residents concerned Israel is changing their residency rights - Arabnews - May 2nd, 2020
- Four UTSW Researchers Named to The National Academy of Sciences - D Magazine - May 1st, 2020
- CHMP Grants Positive Opinion for DARZALEX (daratumumab) Subcutaneous Formulation for the Treatment of Patients with Multiple Myeloma - Yahoo Finance - May 1st, 2020
- Verify the URL - InnovationMap - May 1st, 2020
- Houston banking exec shares tips for keeping online information secure amid COVID-19 threats - InnovationMap - May 1st, 2020
- Trials and Tribulations: Neurology Research During COVID-19 - Medscape - April 30th, 2020
- Into the Lungs and Beyond - Harvard Medical School - April 30th, 2020
- Five UC San Diego Professors Elected to National Academy of Sciences - UC San Diego Health - April 29th, 2020
- Suffering from ED? Discover how our combined treatments of Hormone Balancing and FDA Approved Acoustic Wave Pulse Therapy Ends Your ED - Magazine of... - April 29th, 2020
- BrainStorm-Cell Therapeutics to Announce First Quarter Financial Results and Provide a Corporate UpdateThursday, May 7, 2020, 8:30 am EDT - BioSpace - April 29th, 2020
- What Is The Economic Value of Receiving CAR T-Cell Therapy in an Outpatient Setting? - AJMC.com Managed Markets Network - April 24th, 2020
- Healing the heart by returning it to its infancy - FierceBiotech - April 24th, 2020
- What Factors Influence Hematological Recovery in Patients Who Receive CAR-T Therapies? - Cancer Therapy Advisor - April 24th, 2020
- Academy adds new members from UW who 'expand the boundaries of knowledge' - University of Wisconsin-Madison - April 24th, 2020
- FDA Approves New Therapy for Triple Negative Breast Cancer That Has Spread, Not Responded to Other Treatments - FDA.gov - April 24th, 2020
- A rampage through the body - Science Magazine - April 24th, 2020
- Israeli COVID-19 treatment with 100% survival rate tested on US patient - The Jerusalem Post - April 21st, 2020
- Stem Cell Therapy: A Promising Treatment for COVID-19? - Technology Networks - April 21st, 2020
- Meet the 5 female finalists for the 2020 M&T Bank John Travers Award - PennLive - April 21st, 2020
- Hackensack Meridian Health Studying the Blood of COVID-19 Survivors - The Ritz Herald - April 15th, 2020
- Reviewing the Latest Treatment Strategies in Patients with Transplant-Eligible Multiple Myeloma - Hematology Advisor - April 9th, 2020
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market Industry Trends and Forecast to 2026 | Takeda Pharmaceutical Company Limited, Cytori... - April 9th, 2020
- Canadian Company STEMCELL Technologies Is an Essential Industry Partner for COVID-19 Research and Vaccine Development - Business Wire - April 9th, 2020
- 3 drug candidates authorized to treat COVID-19 patients - Korea Biomedical Review - April 7th, 2020
- Surgeon offers innovative treatments - Brunswick News - April 7th, 2020
- Health Tech: Dallas-based American Heart Association Awards $14M in Research Grants for Heart, Brain, and COVID-19 Innovation - dallasinnovates.com - April 7th, 2020
- Metrion Biosciences and International Scientific Consortium Publish Data and New Recommendations for in Vitro Risk Assessment of the Cardiac Safety of... - April 7th, 2020
- YOUR HEALTH: Something fishy to help improve eyesight - WQAD.com - April 6th, 2020
- First Two Patients Enrolled in Randomized Phase 2, COVID-19 Trial with Leronlimab; Five More Severely Ill COVID-19 Patients Treated Under Emergency... - April 6th, 2020
- Yiviva Announces Dosing of First Patient in Phase 2b Study of First-Line YIV-906 Plus Sorafenib Combination Therapy in the Treatment of Hepatocellular... - April 6th, 2020
- Coronavirus Business Tracker: How The Private Sector Is Fighting The COVID-19 Pandemic - Forbes - April 6th, 2020
- Treatment with CytoDyn's Leronlimab Indicates Significant Trend Toward Immunological Restoration in Severely Ill COVID-19 Patients - Associated Press - April 6th, 2020
- Coronavirus daily news update, April 6: What to know today about COVID-19 in the Seattle area, Washington state and the nation - Seattle Times - April 6th, 2020
- Celularity and Infectious Disease Research Institute will try out COVID-19 cell therapy - GeekWire - April 3rd, 2020
- Pinprick Blood Test To Identify Antibodies In Patients Approved By FDA - Kaiser Health News - April 3rd, 2020
- CytoDyn CEO Dr. Pourhassan to Appear on Fox Business Network Friday, April 3, 2020 at 2:00 pm ET to Discuss Leronlimab Treatment of 10 Severely Ill... - April 3rd, 2020
- Is There a New CAR T-Cell Treatment for Mantle Cell Lymphoma? - AJMC.com Managed Markets Network - April 3rd, 2020
- North Jersey hitting the surge - Politico - April 3rd, 2020
- PharmAbcine Announces Acceptance of Phase Ib Olinvacimab and Pembrolizuamb Combination Trial in rGBM Patients Abstract at the 2020 ASCO Annual Meeting... - April 3rd, 2020
- A word for those risking their lives amid the coronavirus crisis: Thanks - TwinCities.com-Pioneer Press - April 3rd, 2020
- AML Relapse: How IDH-Inhibitor Drugs Work To Achieve Remission Before Stem-Cell Transplant - SurvivorNet - April 2nd, 2020
- Three Additional Patients with Severe COVID-19 Treated with Leronlimab in New York Medical Center Bringing the Total to 10 Patients - Associated Press - March 31st, 2020
- 2020 Canada Gairdner Awards Recognize World-renowned Scientists for Transformative Contributions to Research That Impact Human Health - Benzinga - March 31st, 2020
- Sales Revenue of Scaffold Technology Market to Escalate in the Coming Years Owing to Rapid Growth in Consumer Adoption 2017 2025 - Lake Shore Gazette - March 31st, 2020
- San Diego Angel Conference Announces Investment of $400,000 in 3 Companies - Times of San Diego - March 31st, 2020
- About Stem Cell Center - March 28th, 2020
- From Bats to Human Lungs, the Evolution of a Coronavirus - The New Yorker - March 28th, 2020
- Leronlimab Used in Seven Patients with Severe COVID-19 Demonstrated Promise with Two Intubated Patients in ICU, Removed from ICU and Extubated with... - March 28th, 2020
- Live Updates: Coronavirus in the Bay Area: Phony Health 'Inspectors' Knocking on Doors -- Don't Let Them In - KQED - March 28th, 2020
- Veterans in Pain helps ease the pain for veterans - Tullahoma News and Guardian - March 25th, 2020
- Disruptions in Cancer Care in the Era of COVID-19 - Medscape - March 21st, 2020
- In vivo Comparison of the Biodistribution and Toxicity of InP/ZnS Quan | IJN - Dove Medical Press - March 21st, 2020
- A new therapeutic approach against COVID-19 Pneumonia - Institute for Ethics and Emerging Technologies - March 15th, 2020
- Toxicity minimal with novel transplantation approach for transfusion-dependent thalassemia - Healio - March 12th, 2020
- OncMadness: Meet the Blue Ribbon Panel - MedPage Today - March 12th, 2020
- Hatteras Island Cancer Foundation Celebrates 20 Years with Upcoming Annual Gala - Island Free Press - March 12th, 2020
- Scientists Grapple with US Restrictions on Fetal Tissue Research - The Scientist - March 2nd, 2020
- CAR T Cells to Go? Outpatient Therapy Can Be Safe - Medscape - February 28th, 2020
- TO YOUR HEALTH: Inflammation can drive triple-negative breast cancer - Dover Post - February 28th, 2020
- Impact of TP53 Mutation Clearance Prior to Allo-SCT - MedPage Today - February 28th, 2020
- Arctic Medical Center: Regenerative Medicine & Stem Cell ... - February 27th, 2020
- New study identifies trigger that turns dormant cancer stem cells into active ones - Benzinga - February 27th, 2020
- Bringing Transplant to More Patients With AML - MedPage Today - February 27th, 2020
- UCLA raises $5.49 billion in one of most ambitious campaigns ever by a public university - UCLA Newsroom - February 27th, 2020